The effect of tesofensine on appetite sensations

Obesity

Volumn 20, Issue 3, 2012, Pages 553-561

  Gilbert, Jo Anne ^a,b   Gasteyger, Christoph ^b   Raben, Anne ^c   Meier, Dieter H ^c   Astrup, Arne ^b   Sjödin, Anders ^b  

^a UNIVERSITÉ LAVAL   (Canada)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c NEUROSEARCH A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TESOFENSINE;

ADULT; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; FEEDING BEHAVIOR; FEMALE; FOOD INTAKE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBESITY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SATIETY; WEIGHT CHANGE; WEIGHT CONTROL; WEIGHT REDUCTION;

ADULT; ANTI-OBESITY AGENTS; APPETITE REGULATION; BICYCLO COMPOUNDS, HETEROCYCLIC; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; OBESITY; SATIATION; TIME FACTORS; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 84857686801     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1038/oby.2011.197     Document Type: Article

References (40)

1. James WP. The epidemiology of obesity: the size of the problem. J Intern Med 2008;263:336-352.
2. WHO. Obesity and overweight. World Health Organization. 2003.
3. Curioni CC, Lourenço PM. Long-term weight loss after diet and exercise: a systematic review. Int J Obes (Lond) 2005;29:1168-1174.
4. Wing RR, Hill JO. Successful weight loss maintenance. Annu Rev Nutr 2001;21:323-341.
5. Summerbell CD, Cameron C, Glasziou PP. Withdrawn: Advice on low-fat diets for obesity. Cochrane Database Syst Rev 2008:CD003640.
6. Swinburn B, Sacks G, Ravussin E. Increased food energy supply is more than sufficient to explain the US epidemic of obesity. Am J Clin Nutr 2009;90:1453-1456.
7. Doucet E, Imbeault P, St-Pierre S et al. Appetite after weight loss by energy restriction and a low-fat diet-exercise follow-up. Int J Obes Relat Metab Disord 2000;24:906-914.
8. Drapeau V, King N, Hetherington M et al. Appetite sensations and satiety quotient: predictors of energy intake and weight loss. Appetite 2007;48:159-166.
9. Gilbert JA, Drapeau V, Astrup A, Tremblay A. Relationship between dietinduced changes in body fat and appetite sensations in women. Appetite 2009;52:809-812.
10. Pasman WJ, Saris WH, Westerterp-Plantenga MS. Predictors of weight maintenance. Obes Res 1999;7:43-50.
11. Cameron JD, Goldfield GS, Cyr MJ, Doucet E. The effects of prolonged caloric restriction leading to weight-loss on food hedonics and reinforcement. Physiol Behav 2008;94:474-480.
12. Wing RR, Sinha MK, Considine RV, Lang W, Caro JF. Relationship between weight loss maintenance and changes in serum leptin levels. Horm Metab Res 1996;28:698-703.
13. Sinha MK, Caro JF. Clinical aspects of leptin. Vitam Horm 1998;54:1-30.
14. Heini AF, Lara-Castro C, Kirk KA et al. Association of leptin and hunger-satiety ratings in obese women. Int J Obes Relat Metab Disord 1998;22:1084-1087.
15. Rosenbaum M, Sy M, Pavlovich K, Leibel RL, Hirsch J. Leptin reverses weight loss-induced changes in regional neural activity responses to visual food stimuli. J Clin Invest 2008;118:2583-2591.
16. De Vriese C, Delporte C. Influence of ghrelin on food intake and energy homeostasis. Curr Opin Clin Nutr Metab Care 2007;10:615-619.
17. Cummings DE, Weigle DS, Frayo RS et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med 2002;346:1623-1630.
18. Pfluger PT, Kampe J, Castaneda TR et al. Effect of human body weight changes on circulating levels of peptide YY and peptide YY3-36. J Clin Endocrinol Metab 2007;92:583-588.
19. Roth CL, Enriori PJ, Harz K et al. Peptide YY is a regulator of energy homeostasis in obese children before and after weight loss. J Clin Endocrinol Metab 2005;90:6386-6391.
20. de Luis DA, Gonzalez Sagrado M, Conde R, Aller R, Izaola O. Decreased basal levels of glucagon-like peptide-1 after weight loss in obese subjects. Ann Nutr Metab 2007;51:134-138.
21. Adam TC, Jocken J, Westerterp-Plantenga MS. Decreased glucagon-like peptide 1 release after weight loss in overweight/obese subjects. Obes Res 2005;13:710-716.
22. Thatte U. NS-2330 (Neurosearch). Curr Opin Investig Drugs 2001;2:1592-1594.
23. Ayyad C, Andersen T. Long-term efficacy of dietary treatment of obesity: a systematic review of studies published between 1931 and 1999. Obes Rev 2000;1:113-119.
24. Hansen DL, Toubro S, Stock MJ, Macdonald IA, Astrup A. The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction. Int J Obes Relat Metab Disord 1999;23:1016-1024.
25. Astrup A, Madsbad S, Breum L et al. Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1906-1913.
26. Sjödin A, Gasteyger C, Nielsen ALH et al. The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderate obese men. Int J Obes. Epub ahead of print 18 May 2010.
27. Axel AM, Mikkelsen JD, Hansen HH. Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of alpha1 adrenoceptor and dopamine D1 receptor pathways in the dietinduced obese rat. Neuropsychopharmacology 2010;35:1464-1476.
28. Flint A, Raben A, Blundell JE, Astrup A. Reproducibility, power and validity of visual analogue scales in assessment of appetite sensations in single test meal studies. Int J Obes Relat Metab Disord 2000;24:38-48.
29. Sloth B, Due A, Larsen TM et al. The effect of a high-MUFA, low-glycaemic index diet and a low-fat diet on appetite and glucose metabolism during a 6-month weight maintenance period. Br J Nutr 2009;101:1846-1858.
30. Vuksan V, Panahi S, Lyon M et al. Viscosity of fiber preloads affects food intake in adolescents. Nutr Metab Cardiovasc Dis 2009;19:498-503.
31. Chaput JP, Gilbert JA, Gregersen NT, Pedersen SD, Sjödin AM. Comparison of 150-mm versus 100-mm visual analogue scales in free living adult subjects. Appetite 2010;54:583-586.
32. Lehr T, Staab A, Tillmann C et al. Population pharmacokinetic modelling of NS2330 (tesofensine) and its major metabolite in patients with Alzheimer's disease. Br J Clin Pharmacol 2007;64:36-48.
33. Hansen HH, Hansen G, Tang-Christensen M et al. The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: comparison to sibutramine and rimonabant. Eur J Pharmacol 2010;636:88-95.
34. Seeman P, Madras B. Methylphenidate elevates resting dopamine which lowers the impulse-triggered release of dopamine: a hypothesis. Behav Brain Res 2002;130:79-83.
35. Lehr T, Staab A, Tillmann C et al. Contribution of the active metabolite M1 to the pharmacological activity of tesofensine in vivo: a pharmacokineticpharmacodynamic modelling approach. Br J Pharmacol 2008;153:164-174.
36. Nelson DL, Gehlert DR. Central nervous system biogenic amine targets for control of appetite and energy expenditure. Endocrine 2006;29:49-60.
37. Jackson HC, Bearham MC, Hutchins LJ et al. Investigation of the mechanisms underlying the hypophagic effects of the 5-HT and noradrenaline reuptake inhibitor, sibutramine, in the rat. Br J Pharmacol 1997;121:1613-1618.
38. Billes SK, Cowley MA. Inhibition of dopamine and norepinephrine reuptake produces additive effects on energy balance in lean and obese mice. Neuropsychopharmacology 2007;32:822-834.
39. Sloth B, Davidsen L, Holst JJ, Flint A, Astrup A. Effect of subcutaneous injections of PYY1-36 and PYY3-36 on appetite, ad libitum energy intake, and plasma free fatty acid concentration in obese males. Am J Physiol Endocrinol Metab 2007;293:E604-E609.
40. McLaughlin PJ, Winston KM, Limebeer CL et al. The cannabinoid CB1 antagonist AM 251 produces food avoidance and behaviors associated with nausea but does not impair feeding efficiency in rats. Psychopharmacology (Berl) 2005;180:286-293.